Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dasatinib Combination for Chronic Lymphocytic Leukemia Patients With Chemo Refractory Disease

NCT01051115 is registered in ClinicalTrials.gov with Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) as lead sponsor.

NCT NCT01051115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01051115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dasatinib Combination for Chronic Lymphocytic Leukemia Patients With Chemo Refractory Disease
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2008
Completion date
January 31, 2016
Enrollment
35 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia